300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Costa Rica
China
Armenia
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Ireland
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
LSK Investment, VC Fund

LSK Investment

VC Fund

Seoul, South Korea

LSK Investment is a Korean venture capital firm that provides long-term capital and management support to venture enterprises. The firm was founded in 2016 and is based in Seoul, Korea.

Total investments:
44
Last investment:
Lead investor:
9%
Fund size:
$15M
Last fund:

Last updated:

Industries LSK Investment invests in

BiotechnologyMedicalHealth CarePharmaceuticalBiopharma

Stages LSK Investment invests in

Series ASeries BSeries CVenture - Series UnknownSeed

Countries LSK Investment invests in

South KoreaUnited States

Round sizes

Series A $1.6M–$14MSeries B $8.3M–$16MSeries C $3.2M–$46M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$1.6M–$14M
Series B
$8.3M–$16M
Series C
$3.2M–$46M

Investment Focus

Industry

  • Biotechnology 21 (48%)
  • Medical 17 (39%)
  • Health Care 15 (34%)
  • Pharmaceutical 10 (23%)
  • Biopharma 9 (20%)
See all 38 industries →

Stage

  • Series A 18 (41%)
  • Series B 12 (27%)
  • Series C 5 (11%)
  • Venture - Series Unknown 4 (9%)
  • Seed 3 (7%)
See all 6 stages →

Country

  • South Korea 36 (82%)
  • United States 1 (2%)

Team

NameTitleInvestmentsLinksEmail
Lee Myung-kwon Managing Director
Managing Director Total investments: 1 Find email

Investments

CompanyDescriptionRoundLinks
IMBiologics is a biotechnology company that develops antibody-based drug candidates for diseases such as cancer and immune-related conditions. It conducts research and development using its own platforms to discover new therapeutic molecules. $29.5M / Series C / Oct 14, 2025
MBD MBD
MBD is a biotechnology company that specializes in 3D cell culture platforms. $11.9M / Series C / Aug 14, 2025
Trioar is a biotechnological research company that manufacture pharmaceutical products and drugs. $16.2M / Series B / Jul 17, 2025
Medi Builder operates as a Medical Accelerator Management Services Organization (MSO), functioning as a non-hospital business agency similar to its subsidiaries, the special-purpose medical companies (SMCs). However, there are significant differences between SMCs and the MSO in terms of capacity for acceleration, growth potential, and exit plans. $10.3M / Series B / Jun 05, 2025
NeuroXT develops software for precision diagnosis that predicts molecular pathology values. It uses magnetic resonance imaging (MRI) data to assess the effects and adverse reactions of specific drugs, supporting evaluation of patient suitability. The system applies image analysis methods to inform treatment decisions for degenerative braindiseases. Series A / Mar 10, 2025
Special Touch Nursing Services provides in-home nursing care, including health assessments, medication management, and non-medical assistance such as personal care, transportation, and household support. The company also offers licensed case management services to assess needs, coordinate care plans, and advocate on behalf of clients and families.Services are delivered by registered nurses, licensed social workers, nursing assistants, and caregivers to support independence and well-being for seniors and disabled individuals. $1.3M / Seed / Nov 20, 2024
Avelos Therapeutics is a precision medicine company in the clinical stage that finds, creates, and sells targeted therapeutics. $12.4M / Series B / May 02, 2024
Refeely is a refill-focused packaging company that offers B2B packaging solutions using refillable paper cartons for products. The company develops eco-friendly refill products and paper-based packaging system. $742.8K / Seed / Mar 29, 2024
Surginex is a biological drug development company that offers molecular biology, genetics, physical, and chemical analysis services. $6.3M / Series B / Mar 28, 2024
Surginex is a biological drug development company that offers molecular biology, genetics, physical, and chemical analysis services. $6.3M / Mar 27, 2024
See all 44 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Singapore
Oceania
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
LATAM
Poland
Oman
Puerto Rico
Guernsey
Cameroon
Andorra
Colombia
Sudan
Costa Rica
China
Armenia
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Ireland
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does LSK Investment invest in?

LSK Investment invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Series B stage. Most of the 44 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is LSK Investment's check size?

LSK Investment typically joins rounds of $1.6M–$14M at Series A, $8.3M–$16M at Series B and $3.2M–$46M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds LSK Investment participates in.

How do I contact LSK Investment?

Public channels for LSK Investment include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at LSK Investment?

The team at LSK Investment includes Lee Myung-kwon (Managing Director). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
LSK Investment LSK Investment Find emails